Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PMVP PMV Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: PMVP
Price (delayed)
$1.08
Market cap
$56.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.18
Enterprise value
$5.87M
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers.
Highlights
The debt has dropped by 92% year-on-year and by 7% since the previous quarter
The quick ratio is up by 39% QoQ
The EPS is up by 11% year-on-year but it has declined by 3.5% since the previous quarter
The company's net income rose by 6% YoY but it fell by 3.7% QoQ
PMVP's equity is down by 25% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of PMVP
Market
Valuations
Earnings
Shares outstanding
51.95M
Market cap
$56.11M
Enterprise value
$5.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.35
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$88.79M
Net income
-$60.88M
EBIT
-$79.17M
EBITDA
-$78.6M
Free cash flow
-$53.18M
Per share
Balance sheet
Liquidity
EPS
-$1.18
EPS diluted
-$1.18
Free cash flow per share
-$1.02
Book value per share
$3.08
Revenue per share
$0
TBVPS
$3.28
Total assets
$170.61M
Total liabilities
$10.5M
Debt
$1.11M
Equity
$160.11M
Working capital
$153.74M
Debt to equity
0.01
Current ratio
16.75
Quick ratio
16.43
Net debt/EBITDA
0.64
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.6%
Return on equity
-32.5%
Return on invested capital
-51.8%
Return on capital employed
-49.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PMVP stock price
How has the PMV Pharmaceuticals stock price performed over time
Intraday
-0.92%
1 week
11.34%
1 month
26.73%
1 year
-37.93%
YTD
-28.48%
QTD
-0.92%
Financial performance
How have PMV Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$88.79M
Net income
-$60.88M
Gross margin
N/A
Net margin
N/A
PMVP's operating income is down by 16% YoY and by 3.9% from the previous quarter
The company's net income rose by 6% YoY but it fell by 3.7% QoQ
Price vs fundamentals
How does PMVP's price correlate with its fundamentals
Growth
What is PMV Pharmaceuticals's growth rate over time
Valuation
What is PMV Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 11% year-on-year but it has declined by 3.5% since the previous quarter
PMVP's price to book (P/B) is 85% less than its 5-year quarterly average of 2.3 and 13% less than its last 4 quarters average of 0.4
PMVP's equity is down by 25% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is PMV Pharmaceuticals business performance
PMV Pharmaceuticals's ROIC has plunged by 56% YoY and by 19% from the previous quarter
The return on assets has declined by 13% year-on-year and by 12% since the previous quarter
The company's return on equity fell by 12% YoY and by 11% QoQ
Dividends
What is PMVP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PMVP.
Financial health
How did PMV Pharmaceuticals financials performed over time
The total liabilities has dropped by 57% year-on-year and by 31% since the previous quarter
The quick ratio is up by 39% QoQ
The debt is 99% smaller than the equity
The debt has dropped by 92% year-on-year and by 7% since the previous quarter
The company's debt to equity has shrunk by 83% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.